Precipio and Cardinal Health Sign Distribution Agreement for its HemeScreen® Portfolio of Molecular assays for Cancer
Precipio, Inc. has entered into a distribution agreement with Cardinal Health for its HemeScreen molecular assay products. This agreement will allow Cardinal Health to market and distribute Precipio’s HemeScreen portfolio of molecular assays to its customer base, including hospital networks, reference laboratories, and physician-owned laboratories. CEO Ilan Danieli sees this agreement as a significant step in strengthening Precipio's distribution network and positioning the company for growth in 2024.
The distribution agreement between Precipio, Inc. and Cardinal Health represents a strategic move to expand Precipio's market reach for its HemeScreen portfolio. Cardinal Health's extensive distribution network, which spans across acute healthcare systems and various laboratories, can significantly increase the availability and adoption of Precipio's molecular assays. This partnership could potentially lead to an uptick in Precipio's market share and revenue.
From a market perspective, the molecular diagnostics market is experiencing robust growth, driven by technological advancements and a growing emphasis on personalized medicine. Precipio's HemeScreen assays, which cater to these trends, could see heightened demand. The agreement should be seen as a proactive approach to leverage Cardinal Health's market presence to tap into this growing demand, which could, in turn, positively influence Precipio's financial performance in 2024.
Entering into a distribution agreement with a major player such as Cardinal Health is likely to have a positive impact on Precipio's financial health. It is important to analyze the potential increase in sales volumes and the subsequent effect on the company's earnings. The agreement could also lead to improved economies of scale and potentially better margins due to the larger distribution network.
Investors should monitor subsequent quarterly reports to assess the impact of this agreement on Precipio's revenue and profit margins. It is also crucial to consider the contract's terms, such as minimum purchase requirements or volume discounts, which could influence the financial outcomes. The market's reaction to this news will be telling, as it will reflect the anticipated effect on Precipio's future cash flows and valuation.
The significance of this agreement extends into the realm of medical research and patient care. HemeScreen assays are designed to identify genetic mutations associated with various hematologic malignancies, enabling more accurate diagnoses and personalized treatment plans. By partnering with Cardinal Health, Precipio's products could see increased utilization in clinical settings, potentially leading to better patient outcomes.
It is also worth noting the competitive landscape of molecular diagnostics and how this agreement might affect Precipio's standing. The ability to distribute through Cardinal Health could provide Precipio with a competitive edge over other diagnostic companies, especially in terms of reaching a broader client base within the healthcare industry. The long-term implications for medical research include possible advancements in hematology diagnostics and a stronger evidence base for the efficacy of Precipio's assays.
02/06/2024 - 10:00 AM
NEW HAVEN, Conn., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) Cardinal Health
Under the agreement, Cardinal Health will market and distribute Precipio’s HemeScreen portfolio of molecular assays to its customer base, which comprises primarily the acute healthcare systems (hospital networks), as well as reference laboratories and physician owned laboratories.
About Cardinal Health cardinalhealth.com
About Precipio www.precipiodx.com .
Please follow us on LinkedIn @PrecipioDx Facebook
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the targets set herein and related timing.
Except for historical information, statements about future volumes, sales, growth, costs, cost savings, margins, earnings, earnings per share, diluted earnings per share, cash flows, plans, objectives, expectations, growth or profitability are forward-looking statements based on management’s estimates, beliefs, assumptions and projections. Words such as “could,” “may,” “expects,” “anticipates,” “will,” “targets,” “goals,” “projects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “predicts,” and variations on such words, and similar expressions that reflect our current views with respect to future events and operational, economic and financial performance, are intended to identify such forward-looking statements. These forward-looking statements are only predictions based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, Quarterly Report on Form 10-Q for the three months ended September 30, 2023, and our other reports filed with the U.S. Securities and Exchange Commission. Any such forward-looking statements represent management’s estimates as of the date of this press release only. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
What is the distribution agreement between Precipio, Inc. and Cardinal Health about?
The distribution agreement is for Precipio's HemeScreen molecular assay products.
Who will market and distribute Precipio's HemeScreen portfolio of molecular assays under the agreement?
Cardinal Health will market and distribute Precipio's HemeScreen portfolio.
Who are the primary customer bases for Cardinal Health?
Cardinal Health's customer base primarily includes acute healthcare systems (hospital networks), reference laboratories, and physician-owned laboratories.
What does Precipio's CEO, Ilan Danieli, say about the agreement with Cardinal Health?
Ilan Danieli sees this agreement as a significant step in strengthening Precipio's distribution network and positioning the company for growth in 2024.
